VYNE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.25 USD | -5.46% |
|
-11.42% | -3.43% |
| Jun. 07 | Top Premarket Gainers | MT |
| Jun. 05 | VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 32.69M | - | - | - | |||
| 765B | ||||||
| 354B | - | - | - | - | ||
| 331B | ||||||
| 299B | ||||||
| 248B |
